Skip to content
← Full study record

NCT02823327 · OUTCOME

Differential Gene Expression Profile by RNA-Seq or GeneChip Assays

Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma · Source last updated 2025-05-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Number of overexpressed genes
Interval / dispersion
Not reported
Time frame
baseline

What was measured

The resultant data will be a subset of the whole analysis population due to RNAseq data availability. It will be assessed for quality, normalized, and then analyzed for differential gene expression. The Nanostring software nSolver will be used to do quality control, background subtraction, normalization, and analysis of the differential expression for RNA-sequencing data. Lastly, bioinformatic analysis approaches will be used to help make sense of possible biological links between the genes found to be differentially expressed between the sample groups that may be of prognostic significance. 19 Genes with p-value less than 0.05 were reported by the level of gene expression.

Analysis population: RNAseq data were available from 20 participants among 25 participants.

Groups in this outcome

Survival Less Than 2 Years With Available RNAseq Data

7 participants had RNAseq data among 8 participants with survival less than 2 years.

Survival More Than or Equal to 2 Years With Available RNAseq Data

13 participants had RNAseq data among 17 participants with survival more than or equal to 2 years.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Survival Less Than 2 Years With Available RNAseq Data7
Survival More Than or Equal to 2 Years With Available RNAseq Data13

Reported measurements

Source class 1
Values in Number of overexpressed genes · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Survival Less Than 2 Years With Available RNAseq Data4Not reportedNot reportedNot reportedNot reported
Survival More Than or Equal to 2 Years With Available RNAseq Data15Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        4
      2. group Id
        OG001
        value
        15
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    2. group Id
      OG001
      value
      13
    units
    Participants
description
The resultant data will be a subset of the whole analysis population due to RNAseq data availability. It will be assessed for quality, normalized, and then analyzed for differential gene expression. The Nanostring software nSolver will be used to do quality control, background subtraction, normalization, and analysis of the differential expression for RNA-sequencing data. Lastly, bioinformatic analysis approaches will be used to help make sense of possible biological links between the genes found to be differentially expressed between the sample groups that may be of prognostic significance. 19 Genes with p-value less than 0.05 were reported by the level of gene expression.
groups
  1. description
    7 participants had RNAseq data among 8 participants with survival less than 2 years.
    id
    OG000
    title
    Survival Less Than 2 Years With Available RNAseq Data
  2. description
    13 participants had RNAseq data among 17 participants with survival more than or equal to 2 years.
    id
    OG001
    title
    Survival More Than or Equal to 2 Years With Available RNAseq Data
param Type
NUMBER
population Description
RNAseq data were available from 20 participants among 25 participants.
reporting Status
POSTED
time Frame
baseline
title
Differential Gene Expression Profile by RNA-Seq or GeneChip Assays
type
PRIMARY
unit Of Measure
Number of overexpressed genes

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice